Roche ($RHHBY) - Q3 2010 Earnings Report

FiercePharma says: Roche disappointed analysts this quarter, and its seven percent has been blamed on lower demand for Tamiflu. Sales fell from 12.4 billion Swiss francs to 11.5 billion francs, well below analysts' 11.8 billion francs mark. Revenue slid nine percent to 9 billion francs. The company maintains that they have seen no change in Avastin's sales since Europe decided to review the drug's breast cancer use.

Highlights

  • Sales of cancer medicines continue to grow strongly, rising 8%.
  • Operational Excellence initiative's Group-wide review of structures and processes well under way, with measures to be announced before year-end. Aim is to accelerate productivity improvements and strengthen innovation capacity.
  • Roche named Supersector Leader in Healthcare in the Dow Jones Sustainability Indexes (DJSI) for second year running.
  • Roche confirms full-year outlook.

Roche's website: http://www.roche.com/
Full release: Roche release

Roche ($RHHBY) - Q3 2010 Earnings Report
Read more on

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.